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The purpose of this study was to investigate the prognostic value of tumour-associated macrophages with a focus on micro-
anatomical localisation and determine whether molecular changes of the epidermal growth factor receptor (EGFR) are related to
macrophage infiltration in resected non-small cell lung cancer (NSCLC). One hundred and forty-four patients were included in this
study. Immunohistochemistry was used to identify CD68þ macrophages in the tumour islet and surrounding stroma. Epidermal
growth factor receptor mutations were studied by direct sequencing. The EGFR gene copy number and protein expression were
analysed by fluorescence in situ hybridisation and immunohistochemistry. Patients with a high tumour islet macrophage density
survived longer than did the patient with a low tumour islet macrophage density (5-year overall survival rate was 63.9 vs 38.9%,
P¼0.0002). A multivariate Cox proportional hazard analysis revealed that the tumour islet macrophage count was an independent
prognostic factor for survival (hazard ratio 0.471, 95% confidence interval 0.300–0.740). However, EGFR mutations, gene copy
number, and protein expression were not related to the macrophage infiltration. In conclusion, tumour islet macrophage infiltration
was identified as a strong favourable independent prognostic marker for survival but not correlated with the molecular changes of the
EGFR in patients with resected NSCLC.
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It is well known that macrophages infiltrate into tumour tissue
(Svennevig and Svaar, 1979). Generally, macrophages were thought
to have a tumour cell killing function through secretion of
cytotoxic molecules such as tumour necrosis factor-a (Bonta and
Ben-Efraim, 1993) and nitrogen oxide (Cui et al, 1994). However,
several experimental findings have supported a role for macro-
phages in enhancing tumour progression through production of
growth and angiogenic factors including the epidermal growth
factor, transforming growth factor-b, and vascular endothelial
growth factor (Xiong et al, 1998; Leek and Harris, 2002).
The studies with clinical samples to date also have shown
contradictory results. Some studies have shown that macrophage
infiltration was associated with a poor prognosis in breast (Leek
et al, 1996), prostate (Lissbrant et al, 2000), and bladder cancer
(Hanada et al, 2000). However, other studies have shown that
macrophage infiltration was associated with good prognosis in
prostate (Shimura et al, 2000) and colon cancer (Khorana et al,
2003).
For the prediction of prognosis in non-small cell lung cancer
(NSCLC) patients, the results have also been contradictory. Two
studies showed that macrophage infiltration was associated with
a poor prognosis (Takanami et al, 1999; Chen et al, 2003), whereas
two other studies showed that macrophage infiltration was not
related with prognosis (Johnson et al, 2000; Toomey et al, 2003).
Recently, Welsh et al (2005) reported the result of an immuno-
histochemical study with a focus on the micro-anatomical
localisation of macrophages. They showed that the presence of
tumour islet macrophages was related with a good prognosis,
whereas stromal macrophage infiltration was associated with a
poor prognosis in patients with NSCLC. These findings are
consistent with the suggested dual function of macrophages
identified in prior experimental studies. In addition, clinical
studies on gastric, and colon cancer, which analysed macrophage
infiltration with a focus on micro-anatomical localisation, reported
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sthat tumour islet or tumour-front infiltrating macrophages were
associated with a good prognosis (Ohno et al, 2003; Forssell et al,
2007).
Because of the contradictory findings especially with NSCLC,
our goal was to clarify the function of macrophages with regard to
their micro-anatomical localisation in patients with NSCLC.
Besides, to date, it is unclear which factors are important for
macrophage infiltration. The epidermal growth factor receptor
(EGFR) plays a key role in tumour growth, angiogenesis, and
metastasis in NSCLC. In a study on breast cancer specimens, it was
reported that macrophage infiltration was associated with EGFR
protein expression (Leek et al, 2000). In addition, there was
experimental evidence that both macrophages and tumour cells
were necessary and sufficient for comigration and invasion by a
colony-stimulation factor-1/EGF paracine loop (Goswami et al,
2005). Based on these findings, we investigated whether the
macrophage infiltration profile, in NSCLC, was associated with
EGFR mutations, gene copy number or protein expression.
The purpose of this study was to investigate the prognostic value
of tumour-associated macrophages with a focus on the micro-
anatomical localisation and to determine whether molecular
changes in EGFR are associated with macrophage infiltration in
patients with resected NSCLC.
MATERIALS AND METHODS
Clinical samples
Consecutive patients who underwent surgery including lobectomy,
bilobectomy or pneumonectomy for NSCLC between January 1997
and December 1998 at Seoul National University Hospital, Seoul,
Korea and with adequate samples for analyses were included in
this study. Patients with squamous cell carcinoma, adenocarcinoma,
adenosquamous cell carcinoma, and large cell carcinoma were
eligible, but small cell lung cancer, sarcomas, and carcinoid
tumours were excluded. A thorough medical record review for data
including clinical and pathological characteristics such as age,
gender, smoking history, histological subtypes, pathological
stage, recurrence of NSCLC, and survival information was carried
out. Patients who had smoked more than 100 cigarettes during
their lives were defined as smokers.
This study was conducted in compliance with a study protocol
that was approved by the Institutional Review Board of Seoul
National University Hospital.
Immunohistochemisty for CD68þ macrophages
The specimens for immunohistochemical analysis were formalin-
fixed and paraffin-embedded. We used blocks containing only the
advancing edge of the primary tumour. One 4mm section from
each patient was cut onto glass slides. Briefly, the slides were
dewaxed, rehydrated, washed, and subjected to microwave
retrieval in a Tris/EDTA buffer (pH 9.0); they were then immersed
in 3% H2O2. Anti-CD68 antibody (M0876, Dako, Denmark; 1:100)
was used and immunoexpression was detected using a peroxidase-
labelled streptavidin–biotin complex according to the manufac-
turer’s instructions. Meyer’s hematoxylin counterstaining was
performed on the histology slides.
Evaluation of macrophage infiltration
The number of CD68þ macrophages was analysed as previously
described (Welsh et al, 2005). Briefly, the five most representative
high-power fields ( 400) per slide were selected using an
Olympus BX51TF microscope (Olympus, Japan). The area of the
tumour islet and surrounding stroma were measured using LEICA
IM50 image analysis software (Version 4.0, LEICA Microsystems
Imaging Solutions, Cambridge, UK). The number of CD68þ
nucleated cells was counted manually and expressed as cellsmm
3.
For further analysis, the data were divided into two groups with
values above the median or below. The median was chosen as a
cutoff value because the median was the best fitting cutoff when
we compared with different cutoffs including the mean or the
presence/abscence of countable macrophages. To evaluate the
validity of the analysis, the area measurement and counting were
repeated 3 weeks later with 20 cases. All analyses were performed
blind with respect to the clinical outcomes.
DNA sequencing for detection of EGFR mutations
Mutation analysis of EGFR exons 18, 19 and 21 was performed
as previously described (Han et al, 2005). The frequency of EGFR
mutations and their correlation with survival in this study subjects
was previously described in part (Lee et al, 2007). Briefly, DNA was
extracted from five 5-mm paraffin sections, containing a repre-
sentative portion of each tumour block, using QIAamp DNA Mini
kits (Qiagen, Hilden, Germany). One hundred nanograms (ng) of
DNA were amplified in a 20ml reaction solution containing 2ml
of 10  buffer (Roche, Mannheim, Germany), 1.5mM of MgCl2,
0.3mM of each complementary primer, 250mM of deoxynucleoside
triphosphate, and 2.5 units of DNA polymerase (Roche).
Amplifications were performed using a 5min initial denaturation
at 941C; followed by 30 cycles of 1min at 941C, 1min at 551C, and
1min at 721C; and a 10min final extension at 721C. Polymerase
chain reaction products were purified using a QIAgen gel
extraction kit (Qiagen) and DNA sequenced using an ABI-PRISM
BigDye Terminator v3.1 (Applied Biosystems, Foster, CA, USA)
with both forward and reverse sequence-specific primers.
Sequence data were generated using an ABI PRISM 3100 DNA
Analyser (Applied Biosystems), and sequences were analysed using
Sequencer 3.1.1 software (Applied Biosystems) to compare
variations.
Tissue microarray construction
For evaluation of the EGFR gene copy number and protein
expression, we constructed a tissue microarray. Slides of tumour
samples stained with hematoxylin and eosin were reviewed by two
pathologists independently (HSM and DHC) and representative
areas were marked. Core tissue biopsy specimens (2mm in
diameter) in duplicate were obtained from individual paraffin-
embedded samples (donor blocks) and arranged in a new recipient
paraffin block (tissue array block) using a trephine apparatus
(SuperBioChips, Seoul, Korea). Serial sections from the tissue
microarray block were analysed for EGFR gene copy number and
protein expression.
Fluorescence in situ hybridisation
The EGFR gene copy number was analysed using fluorescence
in situ hybridisation (FISH). A dual-probe hybridisation was
performed on 3-mm-thick sections from tissue microarray blocks
using the LSI EGFR SpectrumOrange/CEP7 SpectrumGreen probe
set (Vysis, IL, USA) as described elsewhere (Cappuzzo et al, 2005).
Fluorescence in situ hybridisation signals for each locus-specific
FISH probe were assessed using an Olympus BX51TRF microscope
(Olympus, Japan) equipped with a triple-pass filter (DAPI/Green/
Orange; Vysis, IL, USA). The entire area of the tissue microarray
core was evaluated in each case, and as many nonoverlapping
nuclei as possible were assessed for an orange colour (marker) and
green (reference) signals by a single pathologist (HSM) blinded to
any information about the patients. The EGFR gene copy number
was classified into six categories as described previously
(Cappuzzo et al, 2005): (1) disomy (p2 copies in 490% of cells);
(2) low trisomy (p2c o p i e si nX40% of cells, three copies in 10–40%
of the cells, X4 copies in o10% of cells); (3) high trisomy
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copies in o10% of cells); (4) low polysomy (X4 copies in 10–40%
of cells); (5) high polysomy (X4 copies in X40% of cells) and (6)
gene amplification (defined by presence of tight EGFR gene
clusters and a ratio of EGFR gene to chromosome of X2o rX15
copies of EGFR per cell in X10% of analysed cells). Based on the
EGFR gene copy number, patients were further classified into two
groups, EGFR–FISH positive (high polysomy and gene amplifica-
tion) or EGFR–FISH negative (disomy, low trisomy, high trisomy,
and low polysomy).
Immunohistochemistry for EGFR protein expression
Epidermal growth factor receptor protein expression was evaluated
by immunohistochemistry (IHC) on 4-mm-thick sections from
tissue microarray blocks using mouse anti-human EGFR, clone
31G7 monoclonal antibody (Zymed laboratories, CA, USA) was
used with the labelled streptavidin-biotin complex staining method
(LSAB kit, DAKO, CA, USA). Antigen retrieval was achieved by
proteinase K digestion for 10min, and the primary antibody was
applied at a dilution of 1:50. Two trained pathologists (HSM and
DHC), without knowledge of patient clinical data, scored the
tumour staining. Each cell was scored as 0, 1, 2, or 3, which
corresponded to negative, weak, moderate and strong staining
intensities. The percent stained cells were determined and a final
histochemical score (H-score) was calculated by summing the
products of the staining intensities (0–3) and their distributions
(0–100%). The H-scores ranged from 0 to 300. For statistical
analysis, patients were classified into two groups, EGFR-IHC
positive (H-score; 151–300) or EGFR-IHC negative (H-score:
0–150).
Statistical analysis
The statistical analyses of categorical variables were done using the
Pearson’s w
2 test or Fisher’s exact test where appropriate. The
Spearman’s rank correlation method was used to test for
correlations between paired variables. The Kaplan–Meier survival
analysis was used to estimate the overall survival (Kaplan and
Meier, 1958), and comparisons between groups were done with the
log-rank test. Multivariate logistic analyses were carried out using
a stepwise Cox regression model for overall survival to identify
independent variables and to adjust for baseline characteristics.
Two-sided Po0.05 was considered significant. All analyses were
performed using SPSS Version 12.0 for Windows software package
(SPSS Inc., IL, USA).
RESULTS
Patient characteristics
There were 144 patients included in this study; their clinical and
pathological characteristics are summarised in Table 1. The mean
patient age was 60.4 years (s.d., 8.9) and 74 percent of patients
were male. Fifty-five percent of patients had stage I disease, 17
percent stage II, 29 percent stage IIIA, and 9 percent stage IIIB or
IV. Squamous cell carcinoma histology was present in 51 percent
of patients. Complete resection was performed in 94 percent of
patients. Twenty percent of patients received adjuvant treatments
including radiation (17%) and chemotherapy (3%). The overall
5-year survival rate was 51%.
CD68þ macrophage expression
IHC demonstrated CD68þ macrophages clearly as dark brown-
stained nucleated cells in both the tumour islet and stroma
(Figure 1). The median number of macrophages in the tumour islet
was 28 cellsmm
3 (range, 0–1823) and in the stroma, it was 223
cellsmm
3 (range, 0–1218). When we repeated the macrophage
count in 20 cases to test for validity of the initial counts, good
correlations were found for both the tumour islet (correlation
coefficient 0.975, Po0.0001) and the stroma (correlation coeffi-
cient 0.962, Po0.0001).
EGFR mutation, gene copy number, and protein expression
Epidermal growth factor receptor mutations were found in 29
patients (20.1%). including one patient with exon 18 (E709V)
mutations, 23 with exon 19 (deletion) mutations, and six with exon
21 (L858R) mutations. One patient had exon 18 and 21 mutations
simultaneously. Twenty-six (44%) of the adenocarcinoma patients
had EGFR mutations, whereas only three (3.5%) nonadenocarci-
noma patients had EGFR mutations. Only one patient received
palliative gefitinib treatment after disease recurrence and had a
partial response: this patient had a below median number of
tumour islet macrophages.
Twenty-seven (19%) patients had EGFR–FISH positive tumours
and 31 (22%) had EGFR-IHC positive tumours. The frequency of
EGFR–FISH positive cases was higher in EGFR mutation positive
(P¼0.008) or EGFR-IHC positive tumours (Po0.00001). However,
a correlation between the EGFR mutation frequency and the EGFR-
IHC status was not significant (P¼0.110).
Correlation of macrophage infiltration with clinical and
pathological variables and EGFR status
An analysis of a correlation between the tumour islet or stromal
macrophage counts and other clinical and pathological variables
Table 1 Baseline patient characteristics
Characteristics No of patients (N¼144) %
Sex
Male 106 73.6
Female 38 26.4
Age, years
Mean 60.4
s.d. 8.9
TNM stage
IA 25 17.4
IB 54 37.5
IIA 8 5.6
IIB 17 11.8
IIIA 27 18.8
IIIB 11 7.6
IV 2 1.4
Histology
Adenocarcinoma (Total/BAC) 59/15 41.0/10.4
Squamous cell carcinoma 73 50.7
Adenosquamous 8 5.6
Large cell carcinoma 4 2.8
Smoking history
Never smoked 46 31.9
Smoked 98 68.1
Resection
Complete 136 94.4
Incomplete 8 5.6
Adjuvant treatment
None 115 79.9
Radiation 24 16.7
Chemotherapy 5 3.4
Abbreviations: BAC¼bronchioloalveolar carcinoma; s.d.¼standard deviation.
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copy number, and protein expression were not associated with the
number of macrophages (Table 2).
Survival analysis according to the macrophage counts
Patients with high tumour islet macrophage density survived
longer compared to the patients with low tumour islet macrophage
density group (5-year overall survival rate was 63.9%. for high
tumour islet macrophage vs 38.9% for low tumour islet macro-
phage, P¼0.0002, Figure 2A). The stromal macrophage counts
were not found to be significantly associated with survival
(P¼0.6306, Figure 2B). However, when we analysed survival
according to both the tumour islet and the stromal macrophage
count, high stromal macrophage counts were associated with poor
survival within high or low tumour islet macrophage group
(P¼0.0011, Figure 3A). The total (tumour islet plus stromal)
macrophage count was not significantly correlated with survival
(P¼0.7521, Figure 3B). When we divided the patient groups into
adenocarcinoma and non-adenocarcinoma cases, the tumour islet
macrophage count was a significant prognostic factor for both
patient groups (P¼0.0217, 0.0033, respectively).
Survival analysis according to the clinical and pathological
variables
Among the clinical and pathological variables, the TNM stage, and
complete resection status were significant prognostic factors
(Po0.0001 and P¼0.0118, respectively, Figure 4A and B).
However, the histology group (adenocarcinoma vs nonadenocar-
cinoma), gender (male vs female), age (o60 years vs X61 years),
and smoking status (smoker vs nonsmoker) were not significantly
associated with survival. In addition, EGFR mutations, gene copy
number, and protein expression showed no significant correlation
with survival.
Multivariate analysis for independent prognostic factor
The multivariate Cox proportional hazard analysis, with the
variables significant on the univariate analysis (tumour islet
macrophage counts, TNM stage group, and complete resection
status), revealed that the tumour islet macrophage count was an
independent favourable prognostic factor (hazard ratio 0.471, 95%
A
B
Figure 1 Immunohistochemistry demonstrating the presence of
CD68þ macrophages (brown) in (A) tumour islet and (B) tumour
stroma ( 200).
Table 2 Association of macrophage counts with clinicopathologic and
EGFR status
Characteristics
Tumour islet
macrophage Stromal macrophage
oMedianXMedian P oMedianXMedian P
Total patients (N¼144) 72 72 72 72
Sex
Male 51 55 0.285 48 58 0.088
Female 21 17 24 14
Age
o60 31 38 0.158 39 30 0.182
460 41 34 33 42
Histologic type
Adenocarcinoma 34 25 0.175 32 27 0.498
Nonadenocarcinoma 38 47 40 45
TNM stage
Stage I 35 44 0.264 37 42 0.685
Stage II 13 12 13 12
Stage III/IV 24 16 22 18
Resection
Complete 65 71 0.063 69 67 0.719
Incomplete 7 1 3 5
Smoking status
Nonsmoker 22 24 0.858 25 21 0.592
Smoker 50 48 47 51
EGFR mutation
Absent 56 59 0.678 57 58 1.000
Present 16 13 15 14
EGFR FISH
Negative 50 57 0.410 51 56 0.617
Positive 16 11 15 12
No data 6 4 6 4
EGFR IHC
Negative 55 55 0.833 57 53 0.681
Positive 15 16 14 17
No data 2 1 1 2
Abbreviations: EGFR¼epidermal growth factor receptor; FISH¼fluorescence in situ
hybridization; IHC¼immunohistochemistry.
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stage was also an independent prognostic factor (Po0.0001);
however, the complete resection status was not (Table 3). The
multivariate analysis that incorporated additional covariates
including age, gender, smoking status, and stromal macrophage
count also showed that the tumour islet macrophage count was an
independent favourable prognostic factor (hazard ratio 0.401,
Po0.0001).
0 1000 2000 3000 4000
0.0
0.2
0.4
0.6
0.8
1.0
0 1000 2000 3000 4000
0.0
0.2
0.4
0.6
0.8
1.0
<Median
P=0.0002 
Follow-up time (days)
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l
A
<Median
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l
P=0.6306 
Follow-up time (days)
B
≥Median
≥Median
Figure 2 Kaplan–Meier overall survival curves stratified according to the tumour islet macrophage density (A) and stromal macrophage density (B).
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Figure 3 Kaplan–Meier overall survival curves stratified according to the tumour islet and stromal macrophage density (A) and total (tumour islet plus
stromal) macrophage density (B). Group 1 (n¼29): patients with high tumour islet and low stromal macrophage density; Group 2 (n¼43): patients with
high tumour islet and high stromal macrophage density; Group 3 (n¼43): patients with low tumour islet and low stromal macrophage density; Group 4
(n¼29): patients with low tumour islet and high stromal macrophage density.
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Figure 4 Kaplan–Meier overall survival curves stratified according to the TNM stage groups (A) and complete resection status (B).
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The result of this study showed that a high number of tumour islet
macrophages were a favourable independent prognostic factor for
survival in patients with resected NSCLC. These findings are
consistent with other studies on the microlocalisation of macro-
phages in NSCLC, gastric cancer, and colon cancer (Ohno et al,
2003; Welsh et al, 2005; Forssell et al, 2007). All of these prior
studies showed that macrophage infiltration in the tumour islet or
tumour-front associated with a good prognosis. Considering the
‘macrophage balance theory’ (Mantovani et al, 1992) and
preclinical evidence for a dual function of macrophages (Bonta
and Ben-Efraim, 1993; Cui et al, 1994; Xiong et al, 1998; Leek and
Harris, 2002), there may be at least two kinds of macrophages in
tumour tissue. One type may have a tumour cell killing function by
production of cytotoxic molecules such as nitrogen oxide and
tumour necrosis factor-a, and the other may have a tumour cell
enhancing function by the secretion of growth factors and/or
angiogenic molecules. In this context, tumour islet macrophages
may represent the tumour killing macrophages. However, the
underlying mechanisms of the different macrophage functions,
according to the micro-anatomical localisation, remain to be
elucidated. Recently, an in vitro coculture study suggested that
tumour cell inhibition by macrophages was partially dependent
on cell-to-cell contact (Forssell et al, 2007). To improve our
knowledge of immunohistochemical findings on clinical samples,
future functional studies with tumour-associated macrophages are
needed.
In an effort to discern the molecular factors that influence
macrophage distribution, we tested the relationship between the
EGFR mutations, gene copy number, and protein expression with
macrophage counts. However, we could not demonstrate any
correlation between the EGFR variables studied and macrophage
distribution. Preclinical evidence has suggested that EGFR
mutations might be related to macrophage migration (Goswami
et al, 2005). However, based on our study results, EGFR mutations,
gene copy number, and protein expression does not appear to be
associated with the distribution of tumour-associated macro-
phages.
The result of this study suggested that the tumour islet
macrophage count is an important clinical determinant of patient
prognosis after surgical resection of NSCLC, independent of the
TNM stage. Therefore, decisions with regard to adjuvant
chemotherapy, especially in the early stage of disease, should
include tumour islet macrophage counts. However, for this
approach to be used in the clinical setting, the standardisation of
a counting method and a clinically practical cutoff value other than
a median number should be established.
In conclusion, tumour islet macrophage infiltration was
identified as a strong favourable independent prognostic marker
for survival in patients with resected NSCLC. However, EGFR
mutations, gene copy number, and protein expression did not
correlate with macrophage infiltration in our patient group. Future
functional studies with tumour-associated macrophages and
clinical studies evaluating tumour islet macrophage counts are
warranted.
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